Across TCGA pan-cancer cohorts, PARVA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PARVA data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PARVA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARVA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, GBM, and CCRCC are the cancer types where PARVA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.505	0.759	.029	14	view →
GBM	DFS	Median	All	0.620	0.847	.002	11	view →
CCRCC	DFS	Quartile	III,IV	0.811	0.327	.005	7	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	7	view →
LSCC	DFS	Quartile	II,III,IV	0.792	1.000	.022	6	view →
LUAD	DFS	Quartile	All	0.707	0.396	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: PARVA tumor-vs-normal RNA expression · all PARVA data types